Alicia Olivo Biography and Net Worth

Executive Vice President, General Counsel & Business Development of NeoGenomics

Ali has been serving as General Counsel since mid-April 2022. She has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for over 5 years, representing the company in its acquisition of Inivata and Trapelo Health, as well as fundraising and governance activities. At NeoGenomics, she has also represented the company in various regulatory matters, including before the College of American Pathologists (CAP), the Office for Civil Rights (OCR), and the Office of Inspector General (OIG).

Prior to joining NeoGenomics, Ali served as a Director at PricewaterhouseCoopers, LLP, negotiating incentives for numerous Fortune 500 clients. She also spent many years at General Electric in various roles increasing in scope and responsibility, including Counsel, where she oversaw incentives negotiations, tax controversy, and government affairs.

What is Alicia C. Olivo's net worth?: The estimated net worth of Alicia C. Olivo is at least $378.28 thousand as of November 25th, 2025. Ms. Olivo owns 31,083 shares of NeoGenomics stock worth more than $378,280 as of December 4th. This net worth evaluation does not reflect any other assets that Ms. Olivo may own. Learn More about Alicia C. Olivo's net worth.
How old is Alicia C. Olivo?: Ms. Olivo is currently 40 years old. There are 6 older executives and no younger executives at NeoGenomics. The oldest executive at NeoGenomics is Mr. Christopher Michael Smith BSc, CEO & Director, who is 61 years old. Learn More on Alicia C. Olivo's age.
How do I contact Alicia C. Olivo?: The corporate mailing address for Ms. Olivo and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Alicia C. Olivo's contact information.
Has Alicia C. Olivo been buying or selling shares of NeoGenomics?: During the last quarter, Alicia C. Olivo has sold $250,992.00 of NeoGenomics stock. Most recently, Alicia C. Olivo sold 20,916 shares of the business's stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a transaction totalling $250,992.00. Following the completion of the sale, the executive vice president now directly owns 31,083 shares of the company's stock, valued at $372,996. Learn More on Alicia C. Olivo's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Stephen Kanovsky (Director), Michael Kelly (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), Alicia Olivo (Executive Vice President, General Counsel & Business Development), David Perez (Director), Jeffrey Sherman (CFO), Robert Shovlin (Insider), Warren Stone (President and Chief Operating Officer), Lynn Tetrault (Director), and Anthony Zook (CEO). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, NeoGenomics insiders bought shares 7 times. They purchased a total of 70,600 shares worth more than $550,438.00. During the last year, insiders at the medical research company sold shares 1 times. They sold a total of 20,916 shares worth more than $250,992.00. The most recent insider tranaction occured on November, 25th when EVP Alicia C Olivo sold 20,916 shares worth more than $250,992.00. Insiders at NeoGenomics own 2.4% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/25/2025.

Alicia C. Olivo Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2025	Sell	20,916	$12.00	$250,992.00	31,083
11/15/2024	Sell	5,175	$15.36	$79,488.00	37,129
2/15/2024	Sell	2,587	$14.96	$38,701.52	34,866
11/17/2023	Sell	2,669	$18.39	$49,082.91	37,140

Alicia C. Olivo Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $12.17

$11.94

$12.26

50 Day Range

MA: $10.21

$7.72

$12.34

2 Week Range

Now: $12.17

$4.72

$19.11

Volume

1,233,955 shs

Average Volume

1,981,554 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Alicia Olivo Biography and Net Worth

What is Alicia C. Olivo's net worth?

How old is Alicia C. Olivo?

How do I contact Alicia C. Olivo?

Has Alicia C. Olivo been buying or selling shares of NeoGenomics?

Who are NeoGenomics' active insiders?

Are insiders buying or selling shares of NeoGenomics?